PRODUCT

Tirzepatide (5 mg Vial)

No short description available.

Quickstart Highlights

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists[3][4].

Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

Molecular Info

Chain Length:39 amino acids
Sequence Type:Dual GLP-1/GIP agonist
Molecular Weight:4,813.55 Da
Amino Acid Sequence:His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys
Modification:C20 fatty diacid conjugation for once-weekly dosing

Research Indications

Weight Loss

moderate

Severe Obesity Management
Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide
Metabolic Syndrome Reversal
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers
Body Composition Optimization
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein

Diabetes

effective

Type 2 Diabetes Management
FDA-approved for T2DM with superior HbA1c reduction (1.5-2.4%) compared to existing GLP-1 agonists and insulin regimens
Insulin Resistance Improvement
Significantly improves insulin sensitivity indices and glucose tolerance in prediabetic, diabetic, and metabolically healthy obese populations
Beta Cell Preservation
Protects pancreatic beta cell function and may help restore glucose-responsive insulin secretion in early diabetes

Cardiovascular

effective

Cardiovascular Risk Reduction
SURPASS-CVOT trial showed 26% reduction in major adverse cardiovascular events in high-risk diabetic patients
Blood Pressure Management
Significant reductions in both systolic (8-12 mmHg) and diastolic blood pressure independent of weight loss effects
Lipid Profile Enhancement
Improves triglycerides (-20-30%), increases HDL cholesterol, reduces small dense LDL particles and apolipoprotein B

Reconstitution

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Interactions

Semaglutide

Avoid Combination

Both are GLP-1 agonists - combining increases hypoglycemia and severe GI side effect risk

Liraglutide

Avoid Combination

Another GLP-1 agonist - dual therapy contraindicated due to additive effects

Insulin

Monitor Combination

May require significant insulin dose reduction due to improved sensitivity and glucose control

Metformin

Synergistic

Complementary mechanisms for diabetes management and weight loss with enhanced efficacy

CJC-1295

Compatible

Growth hormone support may help preserve muscle mass during rapid weight loss

Ipamorelin

Compatible

May help maintain metabolic rate and muscle preservation during caloric restriction

BPC-157

Compatible

No known interactions, may support gut health and reduce GI side effects

5-Amino-1MQ

Compatible

NNMT inhibition may complement GLP-1 effects for enhanced metabolic optimization

Protocol Overview

Goal:Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].
Schedule:Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Dose Range:2.5–15 mg weekly with 4‑week titration intervals.
Reconstitution:2.0 mL per 5 mg vial (2.5 mg/mL) for manageable injection volumes.
Storage:Lyophilized frozen; reconstituted refrigerated for up to 28 days.

Dosage Protocols

Start:2.5 mg once weekly for 4 weeks (initiation dose)[1].
Frequency:Once per week (subcutaneous), same day each week.
Timing:Any time of day; with or without food; rotate injection sites.

Dosage Protocols

Weight loss initiation:2.5mg weeklyOnce weekly
Weight loss progression:5mg weeklyOnce weekly
Weight loss optimization:7.5-10mg weeklyOnce weekly
Maximum weight loss:12.5-15mg weeklyOnce weekly
Diabetes management (mild):5-7.5mg weeklyOnce weekly
Diabetes management (severe):10-15mg weeklyOnce weekly

Route:injectable

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F);

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container[7].
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[8].
For multi‑injection doses, use different sites for each injection on the same day.
Inject slowly; wait a few seconds before withdrawing the needle.
Document weekly dose, date, and injection site to maintain consistency.
Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them[1].

Reconstitution

Remove tirzepatide vial from refrigerator and allow to reach room temperature for 15-20 minutes to prevent condensation
Clean vial tops with alcohol wipes using circular motion from center outward, allow to air dry completely
Calculate appropriate reconstitution volume based on desired concentration using the calculator below
Draw calculated amount of bacteriostatic water into insulin syringe, ensuring no air bubbles
Insert needle into tirzepatide vial at 45-degree angle against the glass wall, NOT directly into powder
Slowly inject BAC water down the side of the vial - inject drop by drop to avoid foaming or protein degradation
Remove needle and gently swirl vial in circular motion - NEVER shake vigorously as this destroys the protein
Allow solution to sit for 2-3 minutes if any cloudiness persists, then swirl gently again until completely clear
Final solution should be completely clear and colorless - any persistent cloudiness indicates degradation
Label vial with reconstitution date and concentration, store in refrigerator at 2-8°C immediately
Use within 28 days of reconstitution, always use fresh needle for each injection, inspect for particles before use

Route:injectable

How It Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors[1][2]. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation[2]. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials[3][4]. Its ~5‑day half‑life enables convenient once‑weekly administration[1].

Lifestyle Factors

Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
Prioritize protein to preserve lean mass during weight loss.
Combine resistance training and aerobic activity to support metabolic health.
Stay hydrated, especially given potential gastrointestinal effects.
Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8][10].
Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy[8].
Dispose of needles and syringes in a sharps container immediately after use[7].

Benefits and Side Effects

Benefits

Glycemic control: Significant HbA1c reductions in type 2 diabetes trials[4][9].
Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses)[3][4].
Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies[9].

Side Effects

Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Tirzepatide (5 mg Vial)

Resources

Categories

Company